Mounjaro injection price in Singapore: from S$488 a month

Yes, Mounjaro (tirzepatide) is available in Singapore on prescription. At GetLean it costs S$488 a month at 2.5 and 5 mg, S$788 at 7.5 and 10 mg and S$1,088 at 15 mg (max dose), all-in with Dr Quek’s reviews, delivery and daily WhatsApp coaching. Book your S$20 video consult; Dr Quek decides if it suits you.

Mounjaro is the name under which tirzepatide is registered here with the Health Sciences Authority, and it is prescription-only (NDF product page). It was first registered on 1 March 2023, for type 2 diabetes only; the KwikPen registrations of 18 June 2025 and the vial registrations of 10 October 2025 carry two indications, type 2 diabetes and weight management (HSA register, NDF). Eighteen tirzepatide products are on the register, in three generations, and the KwikPen's licence holder is DKSH Singapore Pte. Ltd.

Availability in Singapore. This medicine is registered with Singapore's Health Sciences Authority, and its registered indication includes weight management. Which medicine suits a particular person, if any does, is decided by the doctor who assesses them.

Is Mounjaro available in Singapore?

Yes, Mounjaro (tirzepatide) is available in Singapore: it is registered here, including for weight management, and a doctor can prescribe it. It is a once-weekly injection, and the registrations that include weight management are the pre-filled pen (the KwikPen) and the vial. It is prescription-only, so it is not sold over the counter.

As listed in Singapore's National Drug Formulary (updated 9 October 2026), the Mounjaro KwikPen is a prescription-only medicine with DKSH Singapore Pte. Ltd. as the licence holder (NDF product page). The KwikPen entry SIN17258P and the vial entry SIN17351P carry two indications, type 2 diabetes and weight management (NDF KwikPen; NDF vial), while the injection entry SIN16718P carries type 2 diabetes only (NDF). MOH said in September 2024 that GLP-1 drugs can only be dispensed by a registered medical practitioner or a licensed retail pharmacy to a patient with a valid prescription (MOH 2024), and HSA's notice of 25 September 2026 warns against GLP-1 medicines obtained overseas or online without a prescription (HSA 2026). Whether Mounjaro is suitable for a particular person is a doctor's decision after an assessment. Weight loss injections in Singapore sets out the other GLP-1 injections registered here.

GetLean Clinic is licensed by MOH under the Healthcare Services Act 2020, so with us it is a registered doctor and a prescription, not a seller without one: book your consult, and after a video consultation Dr Quek decides whether Mounjaro is suitable for you.

How do I get Mounjaro in Singapore?

You get Mounjaro in Singapore on a prescription from a doctor, after a consultation; at GetLean, that is a video consultation with Dr Quek. A doctor here can prescribe it if they judge it appropriate after assessing you, and at GetLean it takes three steps:

1. Book your consult. Tell us about your health conditions and any GLP-1 medication you already take.
2. A 30-minute video consultation with Dr Quek. He reviews your history and goals and decides whether a GLP-1 medication suits you, and which one. A consultation does not guarantee a prescription.
3. If he prescribes it, the medication is delivered to you, with daily WhatsApp coaching and Dr Quek's monthly reviews.

Book your consult to take the first step.

How much does Mounjaro cost in Singapore?

At GetLean the monthly price follows the Mounjaro dose Dr Quek prescribes, and everything is in it:

Mounjaro dose (once weekly)	GetLean, per month, all-in
2.5 mg	S$488
5 mg	S$488
7.5 mg	S$788
10 mg	S$788
15 mg	S$1,088 (max dose)
First video consultation with Dr Quek (30 minutes)	S$20, refunded in full if he decides medication is not right for you
After the taper: daily coaching and a monthly review, no medication	S$88, if you wish

What the monthly price covers:

• Doctor video consultation and ongoing medical oversight by Dr Quek
• The medication, as prescribed, delivered discreetly to you
• A personalised nutrition and daily activity plan
• Daily WhatsApp coaching, and your care team on WhatsApp from 9am to 9pm every day, Singapore time. Outside those hours an urgent symptom does not wait for a reply: go to an emergency department, or call 995 if it is an emergency.
• Dose reviews that work toward your lowest effective dose

Why the price moves with the dose. The price is set by the dose, so it can change at a monthly review: up to S$788 if Dr Quek steps the dose up past 5 mg (S$1,088 at 15 mg, the max dose), and back to S$488 as he steps it down during the taper. Billing is monthly, with the medication included. Which dose suits you, if any, is Dr Quek's decision at your consultation, and the pricing page sets out the whole programme.

Book your consult with Dr Quek.

What is registered, and why the answer has a date on it

Eighteen products, in three generations (HSA register):

Generation	Presentation	Approved	Indications
SIN16714P and SIN16716P–SIN16720P	injection	1 March 2023	type 2 diabetes only
SIN17257P–SIN17262P	KwikPen	18 June 2025	type 2 diabetes and weight management
SIN17351P–SIN17356P	vial	10 October 2025	type 2 diabetes and weight management

All are classified Prescription Only.

This is the part most coverage gets wrong, in both directions. Section 4.1 of the current registrations carries two headed indications (NDF). Section 4.1 of the 2023 injection registration carries one, and it is diabetes (NDF). Both pages are real, both are current, and a writer who reads either one alone comes away with half the picture.

The accurate sentence is that tirzepatide is registered in Singapore for weight management on its current registrations. A page saying otherwise is describing the 2023 entry.

The two indications, from the label

The type 2 diabetes indication covers adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise, either as monotherapy where metformin is inappropriate or alongside other diabetes medicines.

The weight management indication runs as an adjunct to a reduced-calorie diet and increased physical activity, in adults with an initial BMI of 30 kg/m² or above, or 27 to under 30 in the presence of at least one weight-related comorbid condition — the label names hypertension, dyslipidaemia, sleep apnoea, cardiovascular disease, prediabetes and type 2 diabetes as examples (NDF).

Both are written as an adjunct. The medicine was licensed alongside diet and activity because that is how it was trialled.

The label's BMI numbers, and ours

The label's floor for weight management is a BMI of 30, or 27 to under 30 with a weight-related comorbid condition. Those are international cut-offs, not adjusted for Asian bodies.

Our criteria are a BMI of 25 or more. Anyone can book the first consultation and Dr Quek decides there whether a GLP-1 medication suits you.

They are different numbers answering different questions: the label licenses a product, and our criteria say who the programme is for. Meeting them is not the same as being suitable for treatment, which a doctor decides at the consultation. The three published Singapore BMI scales and how they relate are set out in am I eligible. Questions to take to the doctor before a first dose are in Questions to ask your doctor before starting Mounjaro (tirzepatide).

What the trials showed

SURMOUNT-1 enrolled 2,539 adults with obesity, or overweight with at least one weight-related complication, and without diabetes. Mean weight change at 72 weeks was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, against −3.1% with placebo. In the 15 mg group, 57% lost at least a fifth of their body weight (Jastreboff 2022).

Those are averages in a studied population, with lifestyle support in both arms. Individual results vary and are not guaranteed. How this compares with semaglutide is a question with a direct trial behind it, covered in Wegovy vs Mounjaro and, at Ozempic's diabetes doses, in Mounjaro vs Ozempic. Is Reta stronger than Mounjaro? sets these results beside retatrutide's, as separate trials, and Mounjaro side effects covers the side effects, how long they last and the serious ones.

Weight over time

The loss builds over months rather than weeks, then levels off. In a post hoc analysis of SURMOUNT-1 that included 1,545 adherent participants on tirzepatide, 82% had lost at least 5% of body weight by week 12; of the 18% who had not, 70% had reached 5% by week 24, at the end of dose titration, and 90% by week 72 (Ard 2025). In a second post hoc analysis of the same trial, among adherent participants who lost at least 5%, the median time to a weight plateau was 24 to 36 weeks depending on starting BMI, and close to nine in ten had plateaued by week 72 (Horn 2025). Both analyses cover participants who took most of their assigned doses, in a Lilly-funded trial; individual results vary.

In the Asian trials

Two of the trials ran in East Asia. In SURMOUNT-CN, 210 Chinese adults with obesity or overweight, mean BMI 32.3, lost 13.6% of body weight on average at 52 weeks on 10 mg and 17.5% on 15 mg, against 2.3% on placebo (Zhao 2024). In SURMOUNT-J, in Japanese adults with obesity disease, the difference from placebo in weight change at 72 weeks was 16.1% on 10 mg and 21.1% on 15 mg (Kadowaki 2025). Both were funded by Lilly, and individual results vary. Obesity and GLP-1 in Singapore sets them beside Singapore's own figures.

Why am I gaining weight while using Mounjaro?

Gaining weight while using Mounjaro is not what its trials found on average, and they do not report why it happens to a particular person. In SURMOUNT-1, adults on tirzepatide lost 15.0% to 20.9% of body weight on average over 72 weeks, against 3.1% on placebo, and 85% to 91% lost at least 5%, depending on dose (Jastreboff 2022), so a minority did not reach that mark. The US tirzepatide weight-management label does not list weight gain as a side effect (label searched).

What the trials do show is weight coming back when the dose is lowered or the medicine stopped. In SURMOUNT-MAINTAIN, 25% of adults whose dose was lowered to 5 mg and 67% of those switched to placebo regained more than half their lost weight and were given rescue tirzepatide, against 8% who stayed on their top dose (Horn 2026). A rising weight on treatment is a reason for a review with the prescribing doctor, not for changing the dose yourself; at GetLean that is Dr Quek, at the monthly review. Individual results vary. Book your consult: at GetLean, daily WhatsApp coaching means anything clinical can reach Dr Quek early.

Why it is called a dual agonist

Because it acts at two receptors rather than one: GLP-1, like the rest of the class, and also GIP.

Both are gut hormones released when you eat, and both feed into the systems that govern appetite and blood sugar. Acting at both is the design difference between this molecule and semaglutide, and it is the likeliest explanation for the difference in the trials. The class mechanism is covered in how GLP-1 medications work.

Two things the Singapore label does not carry

No cardiovascular risk-reduction indication. Semaglutide 2.4 mg (Wegovy) has one here; tirzepatide does not. That is a real difference between the two licences and it is not a comment on either medicine.

No sleep apnoea indication. This one matters because a headline exists. A separate United States application for tirzepatide, sold there as Zepbound, had an efficacy supplement approved on 20 December 2024 (Drugs@FDA), and its United States prescribing information carries an indication to treat moderate to severe obstructive sleep apnoea in adults with obesity (DailyMed). That approval is American. It has no effect on what any doctor in Singapore may prescribe, and a Singapore reader acting on it is acting on a licence that does not exist here.

In the Singapore labels, sleep apnoea appears only as one of the comorbidities that can qualify an overweight person for weight management. What weight loss does and does not do for the condition itself is covered in sleep apnoea and body weight.

Zepbound in Singapore: not registered here, but its medicine is

Zepbound is not registered in Singapore: no product with that name appears in the Health Sciences Authority's register of therapeutic products (HSA register). The medicine inside it is. Zepbound is a United States brand of tirzepatide. It was approved by the US Food and Drug Administration on 8 November 2023, on an application of its own, separate from tirzepatide's other United States application (Drugs@FDA). Singapore has not registered that name. Here, tirzepatide's weight-management indication sits on its current Mounjaro registrations (Singapore NDF). Zepbound in Singapore has its own page.

Education only. GetLean does not supply any product sold as Zepbound, and nothing here recommends using one.

The name is not only American. In Japan, tirzepatide's obesity use is also marketed as Zepbound: Eli Lilly Japan lists Zepbound as tirzepatide (Eli Lilly Japan) and describes it as a medicine for obesity (Eli Lilly Japan). Singapore went the other way, keeping one name for both uses. So a search for Zepbound in Singapore is really a search for tirzepatide, and the registered answer is under another name.

Zepbound offered online

Because Zepbound is not registered here, a pack labelled Zepbound offered for sale in Singapore has not been assessed by the Health Sciences Authority. Supplying a counterfeit, adulterated or tampered health product is an offence under the Health Products Act (Health Products Act), and HSA's own testing has found weight-loss products sold online to contain sibutramine, a drug disallowed in Singapore since 2010 because of its heart attack and stroke risk (HSA). On 25 September 2026 HSA warned that GLP-1 medicines, tirzepatide among them, are being touted on social media as quick fixes for weight loss, and that it has received reports of people hospitalised with severe vomiting after using GLP-1 medicines that came from overseas or online sources without a prescription or medical supervision (HSA 2026). The grey-market article covers how to recognise an unlicensed seller and what the law says.

Is Zepbound a long-term solution?

Zepbound is licensed in the United States for long-term use: its US indication is to reduce excess body weight and maintain weight reduction long term, alongside a reduced-calorie diet and more physical activity (DailyMed). Its trials also show what happens when it stops: in SURMOUNT-4, adults switched to placebo after 36 weeks on tirzepatide regained 14.0% of body weight over the following year, while those who stayed on it lost a further 5.5% (Aronne 2024). Zepbound is not registered in Singapore; the same medicine, tirzepatide, is prescribed here as Mounjaro, and GetLean does not supply any product sold as Zepbound.

At GetLean the exit is planned from the first consultation. The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication. Individual results vary.

The number that is not on the label

A 2026 network meta-analysis pooled 262 trials and 99,791 participants across 19 drugs. Tirzepatide reduced fat mass the most, by 25.7% — and lean mass the most, by 8.3% (Nong 2026). Those are pooled trial averages, and individual results vary.

Both halves of that finding are the finding. More total loss is not automatically a better outcome if more of it is muscle, and it is not automatically a worse one either. It means the plan around the medicine — protein, resistance training, the rate of loss — matters more with the most effective agent, not less. We cover what the evidence shows about lean tissue in how much muscle you lose on GLP-1 medication.

Which medicine, if any, is appropriate for someone is a clinical decision made after an assessment. GLP-1 medicines may be dispensed here only against a valid prescription from a registered doctor (MOH 2024).

What happens when Mounjaro is stopped?

In SURMOUNT-4, adults switched to placebo after 36 weeks on tirzepatide regained 14.0% of body weight over the following year (Aronne 2024). Stepping down is a different picture: in SURMOUNT-MAINTAIN, adults who stepped down to a lower dose of tirzepatide after 60 weeks were still 16.6% below their starting weight a year later (Horn 2026). At GetLean the exit is planned from the first consultation, and the dose is stepped down at Dr Quek's monthly reviews; weaning off GLP-1 explains how a planned taper works. We call it the GetLean GLP-1 Taper Plan. Individual results vary, and trial figures describe the populations studied. Never stop or change a prescribed medicine on your own. Coming off Mounjaro walks through the weeks after the last dose, and do you have to take Mounjaro or Wegovy forever? covers how long treatment is meant to last.

Can you microdose Mounjaro?

At GetLean, as part of the GetLean GLP-1 Taper Plan set with Dr Quek: microdosing means taking the medicine below its labelled dose or schedule, and the GetLean GLP-1 Taper Plan gets you there in two ways, and often uses both.

With lower doses, you come down to the dose you were on before and stay there until your hunger and cravings are at a level you can handle: someone who reached their goal on Mounjaro 15 mg might come down to 10 mg, find it hard to keep to their diet, and stay on 10 mg until they are ready. With longer gaps between injections, instead of one injection every 7 days, you might inject every 8, 9 or 10 days. Once you are on the lowest dose (Mounjaro 2.5 mg), injections can move to once every two weeks.

One safety rule: on higher doses (7.5, 10 or 15 mg), if you go more than 10 days without an injection, the taper restarts on a lower dose. Taking a high dose after a long break can cause stomach and gut side effects, including pancreatitis. Speak to us before your next dose. GLP-1 microdosing at GetLean, step by step sets out the whole plan. Book a consultation to plan yours.

What happens after the taper at GetLean?

The plan for coming off is the GetLean GLP-1 Taper Plan: after hitting your goal weight with the right nutrition and exercise habits built, the dose is stepped down at Dr Quek's monthly reviews towards your lowest effective dose and, where clinically appropriate, off the medication.

Finishing the taper does not have to end the support. After the taper, a patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time: a restart begins with a review consultation, and whether to restart the medication is his decision at that review.

Designed to end: a programme whose pace and taper off the medication are planned from the first consult, so the result holds after the medication stops.

Common questions

How much does Mounjaro cost per month in Singapore?

At GetLean, S$488 a month at 2.5 mg and 5 mg, S$788 a month at 7.5 mg and 10 mg, and S$1,088 a month at 15 mg (max dose), all-in: Dr Quek's consultations and reviews, the medication delivered to you, and daily WhatsApp coaching. The first video consultation is S$20, refunded in full if he decides medication is not right for you. The dose, and so the price, is Dr Quek's decision.

Does the price change when the dose changes?

Yes. The monthly price follows the dose: S$488 at 2.5 mg and 5 mg, S$788 at 7.5 mg and 10 mg, and S$1,088 at 15 mg (max dose). It can move up when Dr Quek steps the dose up and back down as he steps it down during the taper. Billing is monthly, with the medication included.

Can a normal GP prescribe Mounjaro?

Yes, if they judge it appropriate after assessing you. Mounjaro is registered in Singapore and classified Prescription Only (HSA register), and GLP-1 medicines here may be dispensed only by a registered doctor or a licensed retail pharmacy, against a valid prescription (MOH 2024). At GetLean, Dr Quek assesses you at a video consultation and, if he finds it clinically appropriate, prescribes it and has it delivered to you, at the monthly prices on this page for the doses it lists.

Is Mounjaro available without a prescription?

No. Mounjaro is classified Prescription Only in Singapore (HSA register), and GLP-1 medicines here may be dispensed only by a registered doctor or a licensed retail pharmacy, against a valid prescription (MOH 2024), so a pharmacy cannot supply it over the counter. HSA has received reports of people hospitalised with severe vomiting after using GLP-1 medicines from overseas or online sellers without a prescription and medical supervision (HSA).

Can I claim Mounjaro on MediSave or insurance?

Not as a condition in its own right: as checked on 7 October 2026, obesity is not one of the 23 chronic conditions covered by MediSave's outpatient scheme (MOH). No GLP-1 medicine for weight is on MOH's list of subsidised drugs or the Healthier SG medication list (MOH; Healthier SG list), and the two Integrated Shield Plan wordings checked exclude treatment for obesity and weight reduction (Singlife; Prudential). MOH's rulebook for covered conditions such as diabetes lists weight-loss medication as claimable if clinically indicated and also as not claimable, and it does not say whether a GLP-1 medicine for weight counts (CDMP Handbook). Other insurers have their own wording, so the exclusions section of your own policy is the place to check; MediSave and insurance for GLP-1 in Singapore goes through each scheme.

Is Mounjaro available in Singapore?

Yes, Mounjaro (tirzepatide) is registered in Singapore, including for weight management, and a doctor here can prescribe it. As listed in Singapore's National Drug Formulary (updated 9 October 2026), it is prescription-only, with DKSH Singapore Pte. Ltd. as the licence holder (NDF product page).

How do I get Mounjaro in Singapore?

You get Mounjaro in Singapore on a prescription from a doctor, after a consultation; at GetLean, that is a 30-minute video consultation with Dr Quek. Book your consult with Dr Quek. Dr Quek decides whether a GLP-1 medication suits you, and if he prescribes it, the medication is delivered to you. A consultation does not guarantee a prescription.

Is Mounjaro approved in Singapore for weight loss?

On its current registrations, yes. The KwikPen registrations from June 2025 and the vial registrations from October 2025 carry two headed indications in section 4.1 — type 2 diabetes mellitus, and weight management (NDF). The older 2023 injection registration carries type 2 diabetes only (NDF).

Why do some pages say it is diabetes-only in Singapore?

Because they are describing the 2023 registration, which is diabetes-only and is still on the register (NDF). Eighteen tirzepatide products are registered here in three generations, and they do not all carry the same indications. Any statement about what tirzepatide is licensed for in Singapore needs to say which registration it means.

Zepbound is approved for sleep apnoea. Does that apply here?

No. Zepbound is tirzepatide under a separate United States application, whose efficacy supplement was approved on 20 December 2024 (Drugs@FDA) and whose United States label carries the sleep apnoea indication (DailyMed). No GLP-1 medicine carries a sleep apnoea indication in Singapore. Sleep apnoea appears in the local weight-management indication only as a comorbidity that can qualify someone for treatment of their weight.

Is Zepbound available in Singapore?

No product named Zepbound is registered in Singapore (HSA register). Its active ingredient, tirzepatide, is registered here under the name Mounjaro, and its current registrations include a weight-management indication (Singapore NDF).

Is Zepbound the same as Mounjaro?

Same molecule, different registrations. Both are tirzepatide. In the United States, Zepbound is the name on a separate application for weight management, approved on 8 November 2023 (Drugs@FDA). In Singapore there is no Zepbound, and tirzepatide's weight-management indication sits on its current Mounjaro registrations (Singapore NDF).

What about Zepbound sold online in Singapore?

A product that is not registered here has not been assessed by Singapore's Health Sciences Authority. Supplying a counterfeit or adulterated health product is an offence under the Health Products Act (Health Products Act), and HSA has found weight-loss products sold online to contain a drug banned in Singapore since 2010 (HSA).

How much weight did people lose in the trials?

In SURMOUNT-1, mean weight change at 72 weeks was −15.0%, −19.5% and −20.9% at the 5 mg, 10 mg and 15 mg doses, against −3.1% with placebo, across 2,539 adults (Jastreboff 2022). Those are trial averages. Individual results vary and are not guaranteed.

Does the label's BMI of 27 mean GetLean's threshold is 27?

No. They are different numbers answering different questions. The registered label sets the floor for that product's weight-management indication. Our criteria are a BMI of 25 or more. Anyone can book the first consultation and Dr Quek decides there whether a GLP-1 medication suits you.

What happens when Mounjaro is stopped?

In SURMOUNT-4, adults switched to placebo after 36 weeks on tirzepatide regained 14.0% of body weight over the following year (Aronne 2024). Stepping down is a different picture: in SURMOUNT-MAINTAIN, adults who stepped down to a lower dose of tirzepatide after 60 weeks were still 16.6% below their starting weight a year later (Horn 2026). At GetLean the exit is planned from the first consultation, and the dose is stepped down at Dr Quek's monthly reviews. Individual results vary.

Can you microdose Mounjaro?

At GetLean, as part of the GetLean GLP-1 Taper Plan set with Dr Quek: microdosing means taking the medicine below its labelled dose or schedule, by lower doses, longer gaps between injections, or both. Someone who reached their goal on Mounjaro 15 mg might come down to 10 mg and stay there until they are ready; instead of one injection every 7 days, you might inject every 8, 9 or 10 days; and once you are on the lowest dose (Mounjaro 2.5 mg), injections can move to once every two weeks. On higher doses (7.5, 10 or 15 mg), if you go more than 10 days without an injection, the taper restarts on a lower dose. Taking a high dose after a long break can cause stomach and gut side effects, including pancreatitis. Speak to us before your next dose.

What happens after the taper at GetLean?

A patient can keep the daily WhatsApp coaching and the monthly reviews with Dr Quek by continuing the monthly subscription, if they wish. If the weight starts coming back, they can come back to Dr Quek at any time; a restart begins with a review consultation, and whether to restart the medication is his decision.

How much weight will I lose in 1 month on tirzepatide?

The trials do not report an average for the first month, which is spent on the 2.5 mg starting dose (Singapore NDF). The earliest common checkpoint is week 12: in a post hoc analysis of SURMOUNT-1, 82% of adherent participants on tirzepatide had lost at least 5% of body weight by then (Ard 2025), and in the full trial the average loss at 72 weeks was 15.0% to 20.9% depending on dose, against 3.1% on placebo (Jastreboff 2022). These are trial averages; individual results vary.

How long does it take for Mounjaro to work?

In SURMOUNT-1, most adherent participants had lost at least 5% of body weight by week 12, and weight then kept falling until it levelled off, at a median of 24 to 36 weeks depending on starting BMI (Ard 2025, Horn 2025). Of those still under 5% at week 12, 90% had reached it by week 72. These are trial averages; individual results vary.